Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Bordignon, Valentina ^a   Cordiali Fei, Paola ^a   Rinaldi, Monica ^b   Signori, Emanuela ^b   Cottarelli, Andrea ^c   Zonfrillo, Manuela ^b   Ensoli, Fabrizio ^a   Rasi, Guido ^b   Fuggetta, Maria Pia ^b  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c CA' FOSCARI UNIVERSITY OF VENICE   (Italy)

Author keywords

BDIX rats; Colon cancer; CTLs; ELISpot; LysiSpot; Tumor antigens

Indexed keywords

BETA GALACTOSIDASE; EPITOPE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR CELL DESTRUCTION; ADAPTIVE IMMUNITY; ANIMAL; COLORECTAL TUMOR; DISEASE MODEL; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ADAPTIVE IMMUNITY; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; EPITOPES; INTERFERON-GAMMA; NEOPLASMS, EXPERIMENTAL; RATS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84856390993     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-9     Document Type: Article

References (42)

1. A comparison and critical analysis of preclinical anticancer vaccination strategies. Kochenderfer JN, Gress RE, Exp Biol Med 2007 232 1130 1141 (Pubitemid 47503054)
2. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Doi A, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T, Cancer
3. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. Schwartzentruber DJ, Lawson DH, et al. N Engl J Med 2011 364 22 2119 2127
4. Vaccination with liposome-DNA complexes elicits enhanced antitumor immunity. U'Ren L, Kedl R, Dow S, Cancer Gene Ther 2006 13 1033 1044 (Pubitemid 44564739)
5. Detection of caspases activation in situ by fluorochrome-labeled inhibitors of caspases (FLICA). Darzynkiewicz Z, Bedner E, Smolewski P, Lee BW, Johnson GL, Methods Mol Biol 2002 203 289 299
6. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L, J Immunol Methods 2005 304 43 59 (Pubitemid 41262219)
7. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. Lin HJ, Cherng JM, Hung MS, Sayion Y, Lin JC, J Biomed Sci 2005 12 925 936 (Pubitemid 43081672)
8. Automated analysis of two- and three-color fluorescent Elispot (Fluorospot) assays for cytokine secretion. Bishop C, Divekar AA, Jiminez-Garcia K, Kobie JJ, Lee FE, Maupin GM, Snyder-Cappione JE, Zaiss DM, Mosmann TR, Comput Methods Programs Biomed 2008 92 1 54 65
9. New approaches for monitoring CTL activity in clinical trials. Malyguine A, Strobl S, Zaritskaya L, Baseler M, Shafer-Weaver K, Adv Exp Med Biol 2007 601 273 284
10. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, et al. J Immunol Methods 1995 12 45 54
11. Single-cytokineproducing. CD4 memory cells predominate in type 1 and type 2 immunity. Karulin AY, Hesse MD, Tary-Lehmann M, Lehmann PV, J Immunol 2000 164 1862 1872 (Pubitemid 30108740)
12. Examination of CD8+ T-cell function in humans using MHC class I tetramers: similar cytotoxicity but variable proliferation and cytokine production among different clonal CD8+ T cells specific to a single viral epitope. Lim DG, Bieganowska Bourcier K, Freeman GJ, Hafler DA, J Immunol 2000 165 6214 6220
13. Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. Slifka MK, Rodriguez F, Whitton JL, Nature 1999 401 76 79
14. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Bachmann MF, Barner M, Viola A, Kopf M, Eur J Immunol 1999 29 291 299 (Pubitemid 29043547)
15. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Snyder JE, Bowers WJ, Livingstone AM, Lee FE, Federoff HJ, Mosmann TR, Nat Med 2003 9 231 235 (Pubitemid 36227727)
16. A new human tumor-associated antigen (TLP) is naturally expressed in rat DHD-K12 colorectal tumor cells. Rasi G, Sinibaldi-Vallebona P, Serafino A, Bernard P, Pierimarchi P, Guarino E, Faticanti-Scucchi L, Graziano P, Guadagni F, Garaci E, Int J Cancer 2000 15 540 545
17. Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats. Sinibaldi Vallebona P, Rasi G, Pierimarchi P, Bernard P, Guarino E, Guadagni F, Garaci E, Int J Cancer 2004 20 70 75 (Pubitemid 38507205)
18. Tumor liberated protein from lung cancer and perspectives for immunotherapy. Tarro G, J Cell Physiol 2009 221 26 30
19. Biomolecular markers of breast cancer. Nicolini A, Carpi A, Tarro G, Front Biosci 2006 1 1818 1843 (Pubitemid 43253397)
20. A new tumour associated antigen of non-small cell lung cancer: tumour liberated proteins (TLP) - a possible new tumor marker. Garaci E, Sinibaldi P, Rasi G, Anticancer Res 1996 16 4B 2253 2255 (Pubitemid 26265574)
21. Antigen specific cytokine responsein pediatric patients with atopic dermatitis. Bordignon V, Sinagra JL, Trento E, Pietravalle M, Capitanio B, Cordiali Fei P, Pediatr Allergy Immunol 2005 16 113 120
22. T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Albers AE, Strauss L, Liao T, Hoffmann TK, Kaufmann AM, Clin Dev Immunol 2010 2010 236378
23. Cytotoxic T-lymphocyte-associated antigen-4. Hodi FS, Clin Cancer Res 2007 15 5238 5242 (Pubitemid 47510345)
24. High throughput T epitope mapping and vaccine development. Li Pira G, Ivaldi F, Moretti P, Manca F, J Biomed Biotechnol 2010 2010 325720
25. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG, Cancer Res 2011 15 1253 1262
26. MHC-peptide tetramers for the analysis of antigen-specific T cells. Sims S, Willberg C, Klenerman P, Expert Rev Vaccines 2010 9 765 774
27. Feedback regulation of proliferation vs. differentiation rates explains the dependence of CD4 T-cell expansion on precursor number. Bocharov G, Quiel J, Luzyanina T, Alon H, Chiglintsev E, Chereshnev V, Meier-Schellersheim M, Paul WE, Grossman Z, Proc Natl Acad Sci USA 2011 22 3318 3323
28. Interferon gamma release assays: principles and practice. Lalvani A, Pareek M, Enferm Infecc Microbiol Clin 2010 28 245 252
29. Cytotoxic T cells. Andersen MH, Schrama D, Thor Straten P, Becker JC, J Invest Dermatol 2006 126 1 32 41 (Pubitemid 43336091)
30. Cross-priming in health and disease. Kurts C, Robinson BW, Knolle PA, Nat Rev Immunol 2010 10 403 414
31. Perforin-mediated target-cell death and immune homeostasis. Voskoboinik I, Smyth MJ, Trapani JA, Nat Rev Immunol 2006 6 940 952 (Pubitemid 44851736)
32. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A, J Immunother 2006 29 328 335 (Pubitemid 44297301)
33. Rapid up-regulation and granule-independent transport of perforin to the immunological synapse define a novel mechanism of antigen-specific CD8+ T cell cytotoxic activity. Makedonas G, Banerjee PP, Pandey R, Hersperger AR, Sanborn KB, Hardy GA, Orange JS, Betts MR, J Immunol 2009 182 5560 5569
34. HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses. Snyder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, Mosmann TR, J Immunol 2006 176 2662 2668 (Pubitemid 43201719)
35. AAV-mediated gene targeting methods for human cells. Khan IF, Hirata RK, Russel DW, Nat Protocols 2011 6 482 501
36. Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. Yin Y, Cao LY, Wu WQ, Li H, Jiang Y, Zhang HF, World J Gastroenterol 2010 16 9 1086 1092
37. The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo. Zhang X, Ge YL, Tian RH, Cell Mol Biol Lett 2009 14 2 305 318
38. Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line. Li H, Cao HF, Wan J, Li Y, Zhu ML, Zhao P, World J Gastroenterol 2007 13 6 934 938 (Pubitemid 46470308)
39. Effects of gastrin 17 on beta-catenin/Tcf-4 pathway in Colo320WT colon cancer cells. Cao J, Yu JP, Liu CH, Zhou L, Yu HG, World J Gastroenterol 2006 12 46 7482 7487 (Pubitemid 46017747)
40. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, Ciccarone VC, Methods 2004 33 2 95 103 (Pubitemid 38569654)
41. Comparison of trasfection efficiency of non viral gene transfer reagent. Yamano S, Dai J, Morsi AM, Molecular Biotechnol 2010 46 287 300
42. Functional heterogeneity of vaccine-induced CD8(+) T cells. Monsurr V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM, J Immunol 2002 168 5933 5942 (Pubitemid 34556184)